New drug shows promise for controlling debilitating spinal arthritis

NCT ID NCT04732117

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested a drug called secukinumab in Chinese adults with active non-radiographic axial spondyloarthritis, a type of inflammatory arthritis that mainly affects the spine and causes significant back pain and stiffness. For the first 16 weeks, some participants received the drug and others received a placebo, after which all participants received the active drug. The main goal was to see if the drug could significantly reduce disease activity, pain, and inflammation compared to the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Hefei, Anhui, 230001, China
Novartis Investigative Site

Hefei, Anhui, 230601, China
Novartis Investigative Site

Beijing, Beijing Municipality, 100044, China
Novartis Investigative Site

Xiamen, Fujian, 361001, China
Novartis Investigative Site

Guangzhou, Guangdong, 510030, China
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Shantou, Guangdong, 515000, China
Novartis Investigative Site

Shenzhen, Guangdong, 518020, China
Novartis Investigative Site

Harbin, Heilongjiang, 150000, China
Novartis Investigative Site

Wuhan, Hubei, 430030, China
Novartis Investigative Site

Changsha, Hunan, 410011, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014010, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Nanjing, Jiangsu, 210009, China
Novartis Investigative Site

Yangzhou, Jiangsu, 225001, China
Novartis Investigative Site

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site

Pingxiang, Jiangxi, 337000, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Linyi, Shandong, 276000, China
Novartis Investigative Site

Ürümqi, Xinjiang, 830001, China
Novartis Investigative Site

Kunming, Yunnan, 650000, China
Novartis Investigative Site

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site

Beijing, 100000, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Bengbu, 233004, China
Novartis Investigative Site

Shanghai, 200040, China
Novartis Investigative Site

Shanghai, 200050, China
Novartis Investigative Site

Tianjin, 300052, China

Conditions

Explore the condition pages connected to this study.

NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS